Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 515

Sort by

Sort Order Select

Journal Articles

Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis

Blood (2024) 144 (Supplement 1): 3514.

https://doi.org/10.1182/blood-2024-211371

Published: 2024

Journal Articles

Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial

Blood (2024) 144 (Supplement 1): 2124.

https://doi.org/10.1182/blood-2024-203864

Published: 2024

Journal Articles

A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

Blood (2024) 144 (Supplement 1): 1047.

https://doi.org/10.1182/blood-2024-211343

Published: 2024

Journal Articles

Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

Blood (2024) 144 (Supplement 1): 506.

https://doi.org/10.1182/blood-2024-203338

Published: 2024

Journal Articles

Impact of Donor Age and Donor-Recipient Sex Mismatch on HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation Outcomes

Yosra M. Aljawai, George Chen, Betul Oran, Warren B. Fingrut, Amin M. Alousi, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, David Marin, Uday Popat, Muzaffar H. Qazilbash, Jeremy Ramdial, Portia Smallbone, Katayoun Rezvani, Richard E. Champlin, Elizabeth J. Shpall, Rohtesh S. Mehta

Blood (2024) 144 (Supplement 1): 7441.

https://doi.org/10.1182/blood-2024-210279

Published: 2024

Journal Articles

Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

Yosra M. Aljawai, Rima M. Saliba, George Chen, Betul Oran, Warren B. Fingrut, Amin M. Alousi, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, David Marin, Amanda L. Olson, Uday Popat, Muzaffar H. Qazilbash, Jeremy Ramdial, Gabriela Rondon, Portia Smallbone, Samer A. Srour, Richard E. Champlin, Elizabeth J. Shpall

Blood (2024) 144 (Supplement 1): 7442.

https://doi.org/10.1182/blood-2024-210407

Published: 2024

Journal Articles

Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis

Sophiya S Sami, Qaiser Bashir, Neeraj Y. Saini, Yosra M. Aljawai, Chitra Hosing, Uday Popat, Melody R. Becnel, Gregory P. Kaufman, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Samer A. Srour

Blood (2024) 144 (Supplement 1): 1923.

https://doi.org/10.1182/blood-2024-211495

Published: 2024

Journal Articles

Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis

Abdullah Faisal Deen, Qaiser Bashir, Neeraj Y. Saini, Yosra M. Aljawai, Chitra Hosing, Uday Popat, Melody R. Becnel, Gregory P. Kaufman, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Elizabeth J. Shpall, Richard E. Champlin, Muzaffar H. Qazilbash, Samer A. Srour

Blood (2024) 144 (Supplement 1): 1922.

https://doi.org/10.1182/blood-2024-211408

Published: 2024

Journal Articles

Primary Induction Failure Acute Myeloid Leukemia: Immediate Use of Allogeneic Stem Cell Transplantation Vs. Further Induction Chemotherapy

Natalie Rafaeli, Rima M. Saliba, Jayastu Senapati, Naval Daver, Portia Smallbone, Partow Kebriaei, David Marin, Uday Popat, Tapan M. Kadia, Farhad Ravandi, George Chen, Richard E. Champlin, Elizabeth J. Shpall, Betul Oran

Blood (2024) 144 (Supplement 1): 2191.

https://doi.org/10.1182/blood-2024-201718

Published: 2024

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

Natalie Rafaeli, David Marin, Celina Ledesma, Nitin Jain, Priti Tewari, Issa F. Khouri, Amanda L. Olson, Gheath Alatrash, Nicholas J. Short, Elias Jabbour, Katy Rezvani, Amin M. Alousi, Uday Popat, Richard E. Champlin, Elizabeth J. Shpall, Partow Kebriaei

Blood (2024) 144 (Supplement 1): 2810.

https://doi.org/10.1182/blood-2024-193954

Published: 2024

Journal Articles

Ten-Year Results of a Phase II Clinical Trial Evaluating Ipilimumab Plus Lenalidomide Combination after Autologous Hematopoietic Cell Transplantation in Patients with Lymphoma

Joseph E. Jabbour, Denái R. Milton, Alison M. Gulbis, Bofei Wang, Fadi G. Haddad, Celina Ledesma, Richard E. Champlin, Padmanee Sharma, Ken H. Young, Issa F. Khouri

Blood (2024) 144 (Supplement 1): 7250.

https://doi.org/10.1182/blood-2024-203392

Published: 2024

Journal Articles

Conditioning with Busulfan + Melphalan Versus Single-Agent Melphalan for Patients with Multiple Myeloma Receiving Autologous Stem Cell Transplantation: A Propensity Score-Matched Analysis

Blood (2024) 144 (Supplement 1): 7019.

https://doi.org/10.1182/blood-2024-203529

Published: 2024

Journal Articles

Second Line Treatment in Patients with Multiple Myeloma Progressing after Bortezomib, Lenalidomide, Dexamethasone Induction, Autologous Transplant and Lenalidomide Maintenance

Blood (2024) 144 (Supplement 1): 7018.

https://doi.org/10.1182/blood-2024-203404

Published: 2024

Journal Articles

Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods

Blood (2024) 144 (Supplement 1): 3817.

https://doi.org/10.1182/blood-2024-210779

Published: 2024

Journal Articles

Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant

Blood (2024) 144 (Supplement 1): 3344.

https://doi.org/10.1182/blood-2024-203700

Published: 2024

Journal Articles

Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma

Blood (2024) 144 (Supplement 1): 5154.

https://doi.org/10.1182/blood-2024-203824

Published: 2024

Journal Articles

Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies

Jeremy Ramdial, Lorlyn Clemente, Pinaki Banerjee, Bouthaina S. Dabaja, Gheath Al-Atrash, Amin M. Alousi, Betul Oran, Uday Popat, Jin S. Im, Samer A. Srour, George Chen, Partow Kebriaei, Chitra Hosing, David Marin, Katayoun Rezvani, Elizabeth J. Shpall, Richard E. Champlin

Blood (2024) 144 (Supplement 1): 4841.

https://doi.org/10.1182/blood-2024-211389

Published: 2024

Journal Articles

Predictors of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide

Rima M. Saliba, Yosra M. Aljawai, Amin M. Alousi, Betul Oran, Uday Popat, Richard E. Champlin, Elizabeth J. Shpall

Blood (2024) 144 (Supplement 1): 4890.

https://doi.org/10.1182/blood-2024-210660

Published: 2024

Journal Articles

Long-Term Follow-up of Crenolanib Maintenance after Allogeneic Transplantation in Newly Diagnosed and Relapsed FLT3 Mutated AML

Betul Oran, David Marin, Qaiser Bashir, Sairah Ahmed, Amanda L. Olson, Uday Popat, Partow Kebriaei, Elizabeth J. Shpall, Vinay Jain, Richard E. Champlin

Blood (2024) 144 (Supplement 1): 1497.

https://doi.org/10.1182/blood-2024-207763

Published: 2024

Journal Articles

HLA-DPB1 Mismatches and the Impact on Unrelated Donor Transplant Outcomes with the Use of Post-Transplant Cyclophosphamide

Portia Smallbone, Kai Cao, Rima M. Saliba, Michele Alvarez, Warren B Fingrut, Yosra Aljawai, Amanda L. Olson, Amin M. Alousi, George Chen, Jeremy Ramdial, Richard E. Champlin, Elizabeth J. Shpall, Betul Oran

Blood (2024) 144 (Supplement 1): 4937.

https://doi.org/10.1182/blood-2024-200238

Published: 2024

NARROW

Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis

Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial

A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

Impact of Donor Age and Donor-Recipient Sex Mismatch on HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation Outcomes

Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis

Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis

Primary Induction Failure Acute Myeloid Leukemia: Immediate Use of Allogeneic Stem Cell Transplantation Vs. Further Induction Chemotherapy

Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

Ten-Year Results of a Phase II Clinical Trial Evaluating Ipilimumab Plus Lenalidomide Combination after Autologous Hematopoietic Cell Transplantation in Patients with Lymphoma

Conditioning with Busulfan + Melphalan Versus Single-Agent Melphalan for Patients with Multiple Myeloma Receiving Autologous Stem Cell Transplantation: A Propensity Score-Matched Analysis

Second Line Treatment in Patients with Multiple Myeloma Progressing after Bortezomib, Lenalidomide, Dexamethasone Induction, Autologous Transplant and Lenalidomide Maintenance

Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods

Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant

Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma

Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies

Predictors of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide

Long-Term Follow-up of Crenolanib Maintenance after Allogeneic Transplantation in Newly Diagnosed and Relapsed FLT3 Mutated AML

HLA-DPB1 Mismatches and the Impact on Unrelated Donor Transplant Outcomes with the Use of Post-Transplant Cyclophosphamide

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only